Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review

The review article discusses the issues of anticoagulant therapy in cardiovascular patients with thrombocytopenia (TP), gives the concept of ethylenediaminetetraacetic acidand heparin-induced TP. The management of patients with heparin-induced TP is analyzed in detail, which consists in the disconti...

Full description

Saved in:
Bibliographic Details
Main Authors: K. G. Pereverzeva, S. S. Yakushin, A. An. Korshikova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2023-09-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/5408
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849341527782850560
author K. G. Pereverzeva
S. S. Yakushin
A. An. Korshikova
author_facet K. G. Pereverzeva
S. S. Yakushin
A. An. Korshikova
author_sort K. G. Pereverzeva
collection DOAJ
description The review article discusses the issues of anticoagulant therapy in cardiovascular patients with thrombocytopenia (TP), gives the concept of ethylenediaminetetraacetic acidand heparin-induced TP. The management of patients with heparin-induced TP is analyzed in detail, which consists in the discontinuation of unfractionated and low molecular weight heparin administration with replacement to direct thrombin inhibitors (lepirudin or argatroban), fondaparinux or direct oral anticoagulants.The authors emphasize that the anticoagulant administration to most patients with platelet count >50×109/l is possible in full prophylactic and therapeutic doses. Reducing the level of platelets to 25-50×109/l in most cases requires a reduction in the anticoagulant dose by 50%. At a platelet level of 20-25×109/l or less, anticoagulant therapy should be avoided in most patients.In addition to the scope of anticoagulant therapy, TP also determines the choice of anticoagulant as follows: in patients with acute coronary syndrome, bivalirudin or fondaparinux are recommended, while in patients with cancer and stable TP, warfarin or direct oral anticoagulants can be prescribed. In progressive TP (if heparin-induced TP is ruled out), low molecular weight heparins should be used.
format Article
id doaj-art-44cf7e368bc84787a5e3e47e1d61d9ee
institution Kabale University
issn 1560-4071
2618-7620
language Russian
publishDate 2023-09-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-44cf7e368bc84787a5e3e47e1d61d9ee2025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202023-09-0128810.15829/1560-4071-202354083873Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature reviewK. G. Pereverzeva0S. S. Yakushin1A. An. Korshikova2I.P. Pavlov Ryazan State Medical UniversityI.P. Pavlov Ryazan State Medical UniversityI.P. Pavlov Ryazan State Medical UniversityThe review article discusses the issues of anticoagulant therapy in cardiovascular patients with thrombocytopenia (TP), gives the concept of ethylenediaminetetraacetic acidand heparin-induced TP. The management of patients with heparin-induced TP is analyzed in detail, which consists in the discontinuation of unfractionated and low molecular weight heparin administration with replacement to direct thrombin inhibitors (lepirudin or argatroban), fondaparinux or direct oral anticoagulants.The authors emphasize that the anticoagulant administration to most patients with platelet count >50×109/l is possible in full prophylactic and therapeutic doses. Reducing the level of platelets to 25-50×109/l in most cases requires a reduction in the anticoagulant dose by 50%. At a platelet level of 20-25×109/l or less, anticoagulant therapy should be avoided in most patients.In addition to the scope of anticoagulant therapy, TP also determines the choice of anticoagulant as follows: in patients with acute coronary syndrome, bivalirudin or fondaparinux are recommended, while in patients with cancer and stable TP, warfarin or direct oral anticoagulants can be prescribed. In progressive TP (if heparin-induced TP is ruled out), low molecular weight heparins should be used.https://russjcardiol.elpub.ru/jour/article/view/5408anticoagulant therapy for thrombocytopeniathrombocytopeniaanticoagulantsheparin-induced thrombocytopeniaethylenediaminetetraacetic acid-induced pseudothrombocytopenia
spellingShingle K. G. Pereverzeva
S. S. Yakushin
A. An. Korshikova
Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
Российский кардиологический журнал
anticoagulant therapy for thrombocytopenia
thrombocytopenia
anticoagulants
heparin-induced thrombocytopenia
ethylenediaminetetraacetic acid-induced pseudothrombocytopenia
title Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
title_full Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
title_fullStr Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
title_full_unstemmed Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
title_short Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
title_sort potential of anticoagulant therapy in cardiology practice for thrombocytopenia literature review
topic anticoagulant therapy for thrombocytopenia
thrombocytopenia
anticoagulants
heparin-induced thrombocytopenia
ethylenediaminetetraacetic acid-induced pseudothrombocytopenia
url https://russjcardiol.elpub.ru/jour/article/view/5408
work_keys_str_mv AT kgpereverzeva potentialofanticoagulanttherapyincardiologypracticeforthrombocytopenialiteraturereview
AT ssyakushin potentialofanticoagulanttherapyincardiologypracticeforthrombocytopenialiteraturereview
AT aankorshikova potentialofanticoagulanttherapyincardiologypracticeforthrombocytopenialiteraturereview